Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Anti-inflammatory therapeutics is a drug class which us used in acute as well as inflammation (redness, swelling and pain). Anti-inflammatory drugs blocks certain chemical mediators in the body which causes inflammation. They are used in treatment of various treatment of many different indications like migraine, headache, rheumatoid arthritis, sprain and menstrual pain. Furthermore, some anti-inflammatory drugs like celecoxib and ibuprofen are being studied for the prevention and treatment of cancer. Additionally, they may provide faster relief with compared to another drugs. They also lowers the levels of prostaglandin and the chemical mediators responsible for inflammations, thereby reducing pain and swelling. Anti-inflammatory drugs usually target the anti-inflammatory mediators or enzymes.
The Asia Pacific anti-inflammatory therapeutics market is witnessing tremendous growth during the forecast period 2021 to 2027. The discovery of the COX isoform led to establishing their importance in many non-arthritic or non-pain states where there is inflammatory component to pathogenesis, comprised of cancer, Alzheimer’s and other neurodegenerative disorders. The major factors such as growing incidences of respiratory diseases and autoimmune conditions is propelling growth of Asia Pacific anti-inflammatory therapeutics market. The strong pipelined drugs is also boosting the growth of Asia Pacific anti-inflammatory therapeutics market. However, lack of timely diagnosis and access to care is hindering the growth of Asia Pacific anti-inflammatory therapeutics market.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the anti-inflammatory therapeutics market. In addition, complete analysis of changes on anti-inflammatory therapeutics organizations expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on Asia Pacific economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The COVID-19 has almost affected every market is healthcare industries positively or negatively. Owing to inflammation caused by COVID-19 virus which causes severe pneumonia the anti-inflammatory therapeutics market is witnessing rapid growth. The cytokine rage is chief cause of death in COVID-19 affected patients. Some of the consequences of severe inflammation and cytokine storm comprised of the acute respiratory distress syndrome, acute lung injury and multiple organ dysfunction syndrome which leads to research and development of anti-inflammatory drugs for treatment of the inflammation caused by the COVID-19. Thus, such factors have impacted positively on the growth of anti-inflammatory therapeutics market during the COVID-19 pandemics.
The Asia Pacific anti-inflammatory therapeutics market is bifurcated by drug class, indication, end user and country.
Drug class like anti-inflammatory biologics, non-steroidal anti-inflammatory drugs, corticosteroids, immune-selective anti-inflammatory derivative and other are comprised in the Asia Pacific anti-inflammatory therapeutics market. Immune-selective anti-inflammatory derivative is also contributing in the growth of Asia Pacific anti-inflammatory therapeutics market. The growing population affected by chronic diseases is propelling growth of Asia Pacific anti-inflammatory therapeutics market. Unavailability of effective treatments is also boosting growth of Asia Pacific anti-inflammatory therapeutics market.
Indication like arthritis, chronic obstructive pulmonary diseases, multiple sclerosis, inflammatory bowel diseases, asthma, tendonitis and other are comprised in the Asia Pacific anti-inflammatory therapeutics market. In which inflammatory bowel diseases is also contributing in the growth Asia Pacific anti-inflammatory therapeutics market. The rising prevalence of osteoarthritis and rheumatoid arthritis is propelling growth of Asia Pacific anti-inflammatory therapeutics market. Growing use of topical drugs for treating arthritis pain is also driving growth of Asia Pacific anti-inflammatory therapeutics market.
End user like hospital pharmacies, online pharmacies and retail pharmacies are comprised in the Asia Pacific anti-inflammatory therapeutics market. In which hospital pharmacies is expected to dominate the market in 2020. The rising prevalence of rheumatoid arthritis is propelling growth of Asia Pacific anti-inflammatory therapeutics market. The rising incidences of respiratory diseases is also boosting growth of Asia Pacific anti-inflammatory therapeutics market.
The Asia Pacific anti-inflammatory therapeutics market is studied for key countries such as India, China, Japan, Australia and South Korea. In which China followed by India and Japan is anticipated to dominate the market in 2020. The rising presence of major key players is propelling growth of Asia Pacific anti-inflammatory therapeutics market. The high expenditures on R&D is also refuelling growth of Asia Pacific anti-inflammatory therapeutics market. Rising use of OTC non-steroidal anti-inflammatory drugs is also driving the growth of Asia Pacific anti-inflammatory therapeutics market.
The major key players operating in the market are Amgen Inc, Astrazeneca Plc., Eli Lily And Company., Hoffmann-La Roche Ag, Glaxosmithkline Plc, Johnson & Johnson, Merck & Co., Inc., Novartis Ag and Pfizer Inc among others.
Jun 2020: FDA approved Novartis Ilaris which contains canakinumab for new indication to treat adult-onset still’s disease (AOSD).
March 2020: GSK’s consumer healthcare launched the biggest innovation in the U.S. as Over the counter oral pain relief category under the brand name of Advil dual action which comprised of the acetaminophen and ibuprofen.
The study comprised of the anti-inflammatory therapeutics market. In which study analysed the various segment of the market such as drug class, indication, end user and country. The study also comprised of dominating segment of the market. The drug class segments is dominated by anti-inflammatory biologics. Likewise, indication segment is dominated by arthritis, end user segment is dominated by hospital pharmacies and country segment is dominated by the China followed India and Japan. The study also covers the impact of COVID-19 on the anti-inflammatory therapeutics market and concludes that the COVID-19 has almost affected every market is healthcare industries positively or negatively. Owing to inflammation caused by COVID-19 virus which causes severe pneumonia the anti-inflammatory therapeutics market is witnessing rapid growth. The cytokine rage is chief cause of death in COVID-19 affected patients. Some of the consequences of severe inflammation and cytokine storm comprised of the acute respiratory distress syndrome, acute lung injury and multiple organ dysfunction syndrome which leads to research and development of anti-inflammatory drugs for treatment of the inflammation caused by the COVID-19. Thus, such factors have impacted positively on the growth of anti-inflammatory therapeutics market during the COVID-19 pandemics. The study also imparts the major key players operating in the market.
Why to buy this report
